DETAILED NOTES ON REZIVERTINIB

BACKGROUNDTriple-unfavorable breast most cancers (TNBC) is highly aggressive with an elevated metastatic incidence compared to other breast cancer subtypes. However, mainly because of the absence of clinically reputable biomarkers and targeted therapy in TNBC, outcomes are suboptimal. As a result, There exists an urgent need to be familiar with bio